PHARMACY

MedPro Rx makes Triangle Business Journal’s fast-growing companies list

BY Alaric DeArment

RALEIGH, N.C. — The Triangle Business Journal has named MedPro Rx to its list of the fastest-growing companies in the North Carolina Research Triangle for the fourth consecutive year, the specialty pharmacy provider said Monday.

MedPro Rx said it had ranked No. 28 on the journal’s 2011 Fast 50 Award list, evaluated by PricewaterhouseCoopers. The company ranked No. 1 in 2008, No. 5 in 2009 and No. 16 in 2010.

"I am deeply gratified that MedPro Rx has received yet another Fast 50 award," president Nancy McFarlane said. "This reflects the commitment of our staff to provide top service to our customers and make sure that we accommodate all of their needs as best as possible."

 


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Amgen drug reduces risk of prostate cancer spreading to bones, study finds

BY Alaric DeArment

THOUSAND OAKS, Calif. — A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.

Published in The Lancet, the phase-3 "147 study" evaluated Xgeva (denosumab) in men with nonmetastatic, castration-resistant prostate cancer, also known as CRPC. The study "significantly prolonged" survival without bone metastasis, delayed time to bone metastasis and reduced the risk of symptomatic bone metastasis. The company has filed a regulatory approval application with the Food and Drug Administration seeking approval for Xgeva to reduce the risk of CRPC spreading to the bones.

"The prevention of bone metastases is a major unmet medical need for men with castration-resistant prostate cancer," Massachusetts General Hospital Cancer Center medical professor Matthew Smith said. "The more than four-month increase in bone metastasis-free survival with Xgeva treatment is a clinically significant finding that has the potential to improve the management of men living with prostate cancer."

 


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Aceto launches generic drugs for infections, malaria

BY Alaric DeArment

PORT WASHINGTON, N.Y. — A subsidiary of Aceto Corp. has launched two generic drugs for treating infectious diseases, the company said Monday.

Aceto said its Rising Pharmaceuticals subsidiary launched flucytosine capsules, a version of Valeant Pharmaceuticals International’s Ancobon, used to treat serious infections; and chloroquine phosphate tablets, a generic version of Sanofi’s malaria drug Aralen. The drugs’ branded versions had sales of $20 million during the 12-month period ended in June, Aceto said.

"The chloroquine phosphate launch marks the first leveraging of a product by Rising that was brought to them directly as a result of Aceto’s worldwide sourcing capabilities," Aceto chairman and CEO Albert Eilender said. "This illustrates the synergistic business opportunities we believe will become more plentiful as we move forward."

 


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?